Multiple-dose phase I trial to evaluate the tolerability and pharmacokinetics of NGX 426 in volunteers.

Trial Profile

Multiple-dose phase I trial to evaluate the tolerability and pharmacokinetics of NGX 426 in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2009

At a glance

  • Drugs Dasolampanel (Primary)
  • Indications Migraine; Neuropathic pain; Pain
  • Focus Adverse reactions
  • Sponsors TorreyPines Therapeutics Inc
  • Most Recent Events

    • 11 Feb 2009 Results were reported in a media release from TorreyPines Therapeutics.
    • 11 Feb 2009 Status changed from recruiting to completed, as reported in media release from TorreyPines Therapeutics.
    • 10 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top